Imaging and diagnostics programs
uTRACE is Curasight’s uPAR-targeted imaging and diagnostic platform. uTRACE and related nine uPAR PET clinical trials have imaged more than 500 patients across eight cancer settings.
curasight.comCrawled Nov 18, 2026
uTRACE is Curasight’s uPAR-targeted imaging and diagnostic platform. uTRACE and related nine uPAR PET clinical trials have imaged more than 500 patients across eight cancer settings.
Built for clinical translation. Curasight has established GMP experience through the uTRACE imaging program and the current 64Cu-DOTA-AE105 glioblastoma study within uTREAT.
uTRACE PET imaging visualizes uPAR in tumors without surgery, tracking radiation distribution.
Radiation delivered by a targeting molecule. Radioligand therapy combines a molecule that recognizes a biological target with a therapeutic radionuclide that deposits radiation in the targeted tissue.
A peptide-based radiopharmaceutical platform. Curasight develops small uPAR-binding peptide ligands that through a chelator can bind a selected radionuclide.
uPAR: a target associated with cancer aggressiveness. Published studies across several cancer types associate higher uPAR expression with more aggressive disease and poorer prognosis.
Peer-reviewed research supporting the uPAR platform.
The United States Patent and Trademark Office announced that Curasight’s U.S. patent application (no. 16/870,776) is ready for allowance.
The page lists Curasight’s upcoming and past investor, scientific, and corporate events, including presentations, conference participation, and hosted gatherings.
Key facts about Curasight, uPAR and the company’s development programs.
Investor and scientific presentation materials. Access current and archived corporate presentations, conference materials and other publicly released presentations.
Company announcements and regulatory disclosures. As a listed clinical-stage company, Curasight communicates material developments through formal market announcements.
The page offers email subscriptions to Curasight’s news, market announcements, press releases, and company updates.
A focused team combining radiopharmaceutical science, clinical development and company building.
Board experience spanning biotechnology, radiopharmaceuticals, oncology, drug development, transactions and capital markets.
To target the biology that makes cancer aggressive. Curasight is pursuing a different biological idea: target uPAR, a receptor associated with the invasive and metastatic phenotype across multiple solid tumors.
From molecular imaging research to a clinical-stage uPAR radiopharmaceutical platform.
For corporate, investor, media and business development enquiries, please contact Curasight in Copenhagen.
One target. Multiple aggressive cancers. Curasight is developing uPAR-targeted radiopharmaceuticals designed to characterize and treat aggressive cancer biology.
Cookie policy, legal notice and GDPR information for the Curasight website.